Dayal Saran

Dr. Saran is a visionary global R&D leader with over 20+ years of expertise in Synthetic Biology and Biotechnology, driving innovation across industries such as environmental sustainability, pharmaceuticals, biofuels, flavors and fragrances, and plant-based foods. As Senior Vice President at Allonnia, Dr. Saran leads multimillion-dollar biomining initiatives and develops groundbreaking biological processes for metal recovery and contaminant degradation. Previously, as part of the founding team, at Motif Foodworks, Dr. Saran pioneered the development of alternative animal proteins. At Synlogic, Dr. Saran spearheaded the advancement of living biotherapeutics for rare diseases. With a proven track record at Ginkgo Bioworks, Evolva, and Codexis, Dr. Saran has consistently delivered high-impact results, meeting critical milestones and securing strategic partnerships. Dr. Saran holds a Ph.D. in Molecular Biology from Indiana University and an M.S. in Bioorganic Chemistry from the Indian Institute of Technology Kanpur (IIT). A prolific inventor and author, Dr. Saran has published extensively in leading peer-reviewed journals and holds multiple patents in synthetic biology. Known for bridging technical innovation with strategic business goals, Dr. Saran continues to shape the future of sustainable biotechnology.

‍

Allonnia

Website

Tuesday

May 06

Securing the Future: Biosecurity Innovations in Synthetic Biology and Allied Technologies

3:30 PM

4:15 PM

The rise of synthetic biology and its various offshoot applications in climate tech, biotech, medtech, foodtech and allied technologies such as DNA data storage presents unprecedented opportunities for innovation and societal benefits, while also creating new challenges in biosecurity. This session will explore strategies to secure the synbio supply chain, opportunities and challenges in scalable containment technologies, traceability systems such as genomic barcoding, deployment of AI solutions for biosecurity, and frameworks for managing the intellectual property (IP) rights of engineered biological assets in a rapidly complexifying supply chain. Our expert panel will discuss the role of emerging technologies in enhancing supply chain transparency, safeguarding against misuse, and ensuring compliance with evolving regulatory landscapes. Join us to gain valuable perspectives on how collaborative public-private efforts, innovative digital and molecular tools, and adaptable regulatory practices can maintain security, foster ethical growth, and protect public trust across the engineering biology ecosystem.